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Economic Evaluation of Add-on Levetiracetam 
for the Treatment of Refractory Partial Epilepsy in Korea 
 
 
 
ObjectiveaaThis study estimated the expected cost-effectiveness ratio expressed as the in-
cremental cost per seizure-free day (SFD) gained and the incremental cost per quality ad-
justed life year (QALY) gained when using levetiracetam (LEV) as add-on therapy from a 
third-party payer perspective. 
MethodsaaA 1-year dose-escalation decision-tree model comparing LEV plus standard the-
rapy (ST) with ST alone was designed to combine transition probabilities, costs and out-
comes. The short-term outcomes and probabilities were derived from a prospective, open-
label clinical trial with 100 Korean adults with refractory partial epilepsy. All data for the 
direct medical costs were derived from Korean cost data extracted from reports published 
by the National Health Insurance Corporation. 
ResultsaaThe average gain in SFDs attributed to LEV add-on was 18.3 days per patient per 
year and the incremental cost-effectiveness ratios (ICERs) for LEV add-on were US$ 44 
per SFD per patient and US$ 11,084 per QALY gained. All sensitivity analyses showed 
that the model was robust to the assumptions made. 
ConclusionaaThe economic evaluation indicates that, given a wide range of assumptions, 
the increased cost of treating patients having refractory partial epilepsy with LEV may be 
partially offset by a reduction in other direct medical costs. This reduction is a consequ-
ence of an increase in the number of SFDs and improved quality of life. 
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Introduction 
 
Epilepsy is a common neurological condition, with an estimated incidence of 50
per 100,000 and prevalence of 5-10 per 1,000 in the developed world.
1 The majority 
of the population with a diagnosis of epilepsy will go into remission when treated with 
an appropriate antiepileptic drug (AED). However, up to 30% will develop refractory 
epilepsy.
2 The majority of patients with refractory epilepsy have localization-related 
(partial) seizures, which are divided into three types: simple partial; complex partial 
and secondarily generalized tonic-clonic seizures.
3 
Over the past two decades there has been a rapid expansion in the number of novel 
AEDs. One such drug is levetiracetam (LEV). LEV is a newer AED that has been ap-
proved as an add-on therapy for refractory partial epilepsy.
4-6 LEV has almost ideal 
pharmacokinetic characteristics that include high oral bioavailability, linear pharma-
cokinetics, low plasma protein binding, primary excretion unchanged in urine, and no
known clinically significant drug-drug interactions, with proven efficacy and toler-
ability.
7,8 Studies have been conducted in several countries including ethnically di-
verse populations and confirmed that ethnicity does not have any impact on the ph-
armacokinetic parameters of LEV.
9,10 
About 95 percent of the Korean population receive health care through national 
 
 
 
 
Economic Evaluation of Add-on Levetiracetam in Korea 
186 Psychiatry Invest 2009;6:185-193 
health insurance, and the remaining 5 percent who are un-
able to pay receive insurance coverage from the govern-
ment. Health care costs are rapidly rising due to charac-
teristics of the health care delivery system and other fac-
tors (i.e., population aging, innovative technologies, and 
higher patient expectation following increasing health 
consciousness). 
In addition to presenting medical, psychological and 
social burdens, epilepsy also constitutes an economic pro-
blem for society. The economic consequences of epile-
psy are manifested both in the direct costs for the treatment 
of the disease and in the indirect costs, which include loss 
of earnings due to reduced productivity.
11 A better un-
derstanding of the economic aspects of epilepsy will as-
sist decision makers in identifying the most cost-effective 
treatment in order to make the best use of limited avail-
able health resources. 
This study aimed to estimate the expected cost-effec-
tiveness ratio expressed as the incremental cost per sei-
zure-free day (SFD) gained and the incremental cost per 
quality adjusted life year (QALY) gained when using LEV 
as add-on therapy compared to standard therapy (ST) alone. 
 
Methods 
 
Economic modelling was used to extrapolate cost and 
outcome estimates over a longer time period than that 
which can be obtained from clinical trial data. This st-
udy was performed through the design of a decision-tree 
model using TreeAge Pro 2006 Suite
® Release 0.2, a he-
alth economic tool for conducting economic evaluations 
(http://www.treeage.com). This economic evaluation was 
performed from the third-party payer perspective (i.e., the 
Korean National Health Insurance Corporation).  
Due to the 1-year time horizon of this economic evalu-
ation, the cost and effectiveness measures were not dis-
counted. 
 
Setting and data collection 
For the economic evaluation the raw data from a de-
tailed, open-label, single-arm clinical trial on the effi-
cacy and safety of LEV in Korea was used.
12 The study 
population consisted of 100 adult patients aged 18 years 
or older who received LEV as add-on therapy in addi-
tion to conventional AEDs. All the patients came from 
nine research centres in Korea and had uncontrolled epi-
lepsy and/or intolerable adverse events on conventional 
AEDs. 
Data from the 16-week clinical trial were recorded pro-
spectively. It consisted of two periods: 1) an up-titration 
period (first 4 weeks) and 2) a maintenance period (for 
the following 12 weeks). For purposes of our analysis, 
data were extracted from the collected dataset for the 
period of 12 weeks before and 16 weeks after the first 
day of add-on therapy of LEV. Recorded data covered 
the following domains: 
• Sociodemographics: age, gender, education, marital 
status, etc 
• Type of epilepsy 
• Seizure frequency for the period of 12 weeks before 
and 16 weeks after the first day of add-on therapy of 
LEV 
• Retention rate of LEV   
• Quality of life (QoL): 31-item Quality of Life in Ep-
ilepsy Inventory (QOLIE-31)13 
When estimates of input parameters were not avail-
able, endorsed comments from the Scientific Advisory 
Board (SAB), convened by the Korean Epilepsy Society, 
were considered. 
 
Epilepsy-related quality of life assessment 
Epilepsy-related QoL was assessed twice using the 
Korean translation of the QOLIE-31 at baseline before 
the beginning of add-on therapy of LEV (Week 0) and at 
the end of the clinical trial (Week 16), or earlier if with-
drawn. The QOLIE-31 is a self-administered question-
naire designed to be completed by patients.
13 Validation 
studies of the QOLIE-31 in different language versions 
also demonstrated good reliabilities and validities.
14-16 QO-
LIE-31 was derived from the longer QOLIE-89, an in-
strument with 17 subscales, including generic and epile-
psy-specific issues, and a separate item on health status 
(not scored).
17 The QOLIE-31 includes 7 subscales: sei-
zure worry, overall QoL, emotional wellbeing, energy-
fatigue, cognitive functioning, medication effects, social 
function, and health status (not scored). The subscale and 
the total scores are calculated according to the algorithm 
defined by the author with scores ranging from 0 to 100 
and higher scores indicating better function.
13 
 
Study model 
A 1-year dose-escalation decision-tree model was de-
signed for economic evaluation of LEV as an add-on th-
erapy and further, was adapted to Korean data.
18,19 Two 
hypothetical cohorts of patients were started either on 
combination therapy (LEV 1,000 mg/day plus ST) or on 
ST alone. For patients in the LEV arm the dose was in-
creased up to 3,000 mg/day if freedom from seizures was 
not attained at lower doses (Figure 1). Patients who st-
arted on ST alone were kept in that arm for the whole 1-
year duration of the economic model. In this model, suc-
cess was defined as freedom from seizure, while failure 
was defined as withdrawal leading to being returned to 
ST in the combination therapy arm or not-seizure-free,  
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continued refractory partial epilepsy state in the ST alone 
arm. All these assumptions were reviewed and endorsed 
by the SAB. 
• Patients stayed on a specific LEV dose for 0.5 mon-
ths before the dose could be maintained, changed, or st-
opped.  
• Patients who experienced intolerable adverse events 
under higher doses of LEV could return to lower doses 
of LEV if they had experienced a relatively significant 
reduction in the frequency of seizures while treated with 
lower doses (i.e., 50% reduction in seizure frequency).  
• Patients who stopped LEV returned to ST alone for 
the remaining period.   
• Costs and outcomes of patients who returned to ST 
alone during LEV treatment were the same as those of 
patients who start with the ST alone. 
• Costs and outcomes of patients who started on ST 
alone remained unchanged for the whole 1-year durat-
ion of the economic model. 
More specifically, patients in the combination therapy 
arm started with LEV 1,000 mg/day plus ST for a 0.5-
month observation period, after which they entered into 
one of the following pathways: 
1) Stayed at LEV 1,000 mg/day plus ST for the re-
mained 11.5 months if they attained complete seizure 
freedom.  
2) Stopped LEV and return to ST alone for 11.5 mon-
ths if they could not tolerate the LEV 1,000 mg/day plus 
ST. 
3) Increased to LEV 2,000 mg/day if not seizure-free 
at the LEV 1,000 mg/day plus ST, but the LEV 1,000 
mg/day dosage was tolerated. 
Patients increased to LEV 2,000 mg/day and main-
tained that dosage for a 0.5-month observation period 
after which they entered one of the following pathways: 
1) Stayed at LEV 2,000 mg/day plus ST for the re-
maining 11 months if they attained complete freedom 
from seizures.   
2) Returned to the LEV 1,000 mg/day plus ST and main-
tain for 11 months if they could not tolerate the daily dose 
of LEV 2,000 mg but experienced significant reduction 
in the frequency of seizures at the LEV 1,000 mg/day 
plus ST. 
3) Stopped LEV and return to ST alone for 11 months 
Not seizure-free 
Seizure freedom 
0.0714 
Retain to 1,000 mg+ST 
0.8462 
0.1538 
Withdrawal 
Seizure freedom 
0.3421 
Retain to 2,000 mg+ST 
Not seizure-free 
Failure/Withdrawal 
Withdrawal 
Return to LEV 1,000 mg+ST 
0.88 
0.12 
0.3333 
0.6667 
0.6579 
0.9286 
LEV 2,000 mg+ST 
0.4634 
Seizure freedom 
Not seizure-free 
0.0909 
0.9091 
Retain on 3,000 mg+ST 
Withdrawal 
Return to LEV 2,000 mg+ST 
0 
1 
0.825 
0.175 
Failure/Withdrawal 
LEV 3,000 mg+ST 
0.5366 
Failure/withdrawl 
0.04 
LEV 1,000 mg+ST 
0.14 
LEV 1,000 mg+ST (add-on) 
LEV 2,000 mg+ST 
0.82 
Success 
0.007 
Failure 
0.993 
ST (standard therapy) 
[Maintenance] 
Choose 
FIGURE 1. Decision tree for the management of treatment of refractory epileptic patients with combination therapy [Levetiracetam (LEV)+ 
standard therapy] versus standard therapy alone.  
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if they could not tolerate LEV 2,000 mg/ day and if they 
did not experience sufficient reduction in the frequency 
of seizures while treated with the 1,000 mg/day plus ST. 
4) Increased dosage to LEV 3,000 mg/day if not sei-
zure-free at the LEV 2,000 mg/day plus ST, but the 2,000 
mg/day dosage was tolerated. 
Patients increased to LEV 3,000 mg/day and maintain 
for a 0.5-month observation period after which they en-
tered one of the following pathways: 
1) Stayed at LEV 3,000 mg/day and ST for the remain-
ed 10.5 months if they attained complete freedom from or 
attained a significant reduction in the frequency of seizures. 
2) Returnedto LEV 2,000 mg/day and maintained for 
10.5 months if they did not tolerate the daily dose of 3,000 
mg but experienced significant reduction in the frequency 
of seizures while treated with LEV 2,000 mg/day. 
3) Stopped LEV and returned to ST alone for 10.5 mon-
ths if they did not experience sufficient reduction in the 
frequency of seizures while treated with any dose of LEV 
add-on therapy. 
The probabilities of each state for the combination th-
erapy (LEV+ST) were derived from the outcomes of the 
16-week duration of the aforementioned, open-label cli-
nical trial.
12 The transition probabilities for ST were ad-
opted from a previous report.
18 
 
Cost estimates 
The economic evaluation focused on the direct medi-
cal costs incurred by the patients from the third-party pa-
yer perspective. LEV has been available since January 
2007. Costs for ST should not include cost for LEV. There-
fore, unit costs were obtained from the “2006 Korean Na-
tional Health Insurance Statistical Year-book” and the 
“2006 Major Health Insurance Statistics”.
20,21 The average 
currency exchange rate in the year of 2006 was 955.51 
Korea Won per US$ 1 (http://www. keb.co.kr/IBS/wel-
come.jsp). Resource use related to the routine care pro-
vided to patients with refractory partial epilepsy could 
not be derived from the aforementioned prospective cli-
nical trial because information on healthcare resource 
utilization had not been collected.
12 Furthermore, speci-
fic data on health resource utilization of patients with 
refractory epilepsy were not available in Korea. There-
fore, routine follow-up of patients with epilepsy in ty-
pical practices was based on national data sources (gross 
costing method).
20 It was assumed that patients with re-
fractory epilepsy would incur higher costs as a consequ-
ence of frequent outpatient visits and hospital admissions. 
Success in the treatment of patients with refractory epi-
lepsy would save greater amounts of money than success 
in all patients with epilepsy. It was also expected that 
use of the costs of all patients with epilepsy could un-
derestimate potential economic benefits in this study. It 
is also a more conservative estimate than the usual cost 
measure. To cover medical costs for patients with re-
fractory partial epilepsy, costs per patient for inpatient, 
outpatient, and pharmacy for a 1-year period were con-
sidered in this study. Costs consist of: inpatient (US$ 
1,841 per person per year); outpatient (US$ 183 per per-
son per year); and pharmacy (US$ 368 per person per 
year) for ST (Table 1); while for combination therapy, 
costs for LEV (US$ 0.97, US$ 1.45, and US$ 2.18 per 
tablet with LEV 250 mg, 500 mg, and 1,000 mg respec-
tively)(http://www.kpis.or.kr/index.jsp) were added to 
the costs for s ST alone.   
Generally speaking, reduced costs are assumed when 
seizures occur less frequently. The SAB endorsed an as-
sumption of a linear relation between costs for inpatient 
and seizure frequency among patients with refractory 
partial epilepsy. For the base case scenario, in patients 
with seizure freedom (seizure frequency=0), the inpa-
tient cost was considered to be zero. The better response 
was assumed for those patients who stayed at a certain 
dose of LEV per the clinician’s judgement that the dose 
was sufficiently effective and tolerable for the patient. 
P
better response=0.5 means that those with a better response 
may only need half the given inpatient cost. On the other 
hand, worse response was assumed for those patients who 
TABLE 1. Unit costs for model input for the economic evaluation of levetiracetam add-on compared with standard therapy alone for the 
treatment of refractory epilepsy 
Unit cost 
Unit cost 
Original value 
(Korean Won)  Converted value  Unit 
Source 
Inpatient 1,759,183 1841.09  US$/Person/Year  Ref.  20 
Outpatient 175,191 0183.35 US$/Person/Year  Ref.  20 
Pharmacy 351,744 0368.12 US$/Person/Year  Ref.  20 
Levetiracetam       HIRA  web. 
250 mg  0,924 0.97  US$/Tab  
500 mg  1,386  1.45  US$/Tab   
1,000 mg  2,079  2.18  US$/Tab   
HIRA: Health Insurance Review & Assessment Service (http://www.hira.or.kr). The average currency exchange rate in 2006 was 955.51 
Korea Won per US$ 1 (http://www.keb.co.kr/IBS/welcome.jsp) 
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returned to a lower dose of LEV per the clinician’s jud-
gement that the patient was unable to tolerate a higher 
dose, but experienced a significant reduction in the fre-
quency of seizures while treated with the lower dose of 
LEV. P
worse response=0.8 means that those patients with 
worse response may need 80% of the inpatient cost. 
 
Effectiveness estimates 
 
Seizure-Free Days Gained 
Effectiveness was measured in terms of SFDs gained 
per year; SFDs are reported days without seizure. The 
metric ‘SFDs gained’ tries to address the patient’s per-
spective by accounting for an improved ability to per-
form daily tasks on a day without seizure.
22 It is also a 
more conservative measure than the usual efficacy meas-
ure based on the reduction of seizure frequency. The impact 
of adding LEV to the number of SFDs per year in patients 
with refractory partial epilepsy was assessed. Effective-
ness estimates used in the CEA are derived from raw data 
from clinical trials in Korea
12 and presented in Table 2. 
 
Quality Adjusted Life Years Gained 
The disease-specific health-status instrument, QOLIE-
31, measures a range of health attributes from its 7 sub-
scales including 1) seizure worry, 2) overall QoL, 3) emo-
tional wellbeing, 4) energy-fatigue, 5) cognitive function-
ing, 6) medication effects, and 7) social function, as well 
as general health status (not scored). Subscale scores 
range from 0 to 100. In their validation paper, the au-
thors who developed the QOLIE reported utility weights 
for above 7 dimensions by using econometric techniq-
ues (i.e., ordinary least squares regression).
13 Utility is a 
measure of the preference for, or desirability of, a spe-
cific level of health state or specific health outcome (on 
a scale of 0 to 1). QoL is measured in utility weights, 
which are used to represent preferences for health states. 
In this study, the utility scores of each patient were cal-
culated as follows:  
Utility of a patient=∑(subscale score i/100)×(weight 
i/sum of weights) 
The mean value of the utilities of patients at each ter-
minal node in the decision-tree model (Figure 1) was as-
signed as a utility, expressed as QALYs gained, at each 
terminal node.   
 
Incremental cost-effectiveness ratio 
Measurement of the incremental cost-effectiveness ra-
tios (ICER), i.e. incremental cost per SFD and the QA-
LY gained, was derived from the trial in Korea. ICER 
was calculated as follows*: 
ICER=(CLEV+ST-CST)/(ELEV+ST-EST)=ΔC/ΔE 
TABLE 2. Probability, cost (US$/year/patient), SFDs and QALYs estimates used in the model
Effectiveness estimates 
Treatment Probability  Cost*  (US$) 
SFDs gained  QALY gained 
Combination therapy  1.00 3,178 340.7 0.6522 
LEV 1,000 mg/day+ST  0.14  2,457  345.3  0.6553 
Seizure freedom  0.01  1,610  365.0  0.9418 
Not seizure-free, but retain  0.11  2,531  347.6  0.6433 
Not seizure-free & withdraw to ST alone  0.02  2,474  322.1  0.5782 
Initiation failure & withdraw to ST alone  0.04  2,433  322.1  0.5782 
LEV 2,000 mg/day+ST  0.38  2,717  352.1  0.6581 
Seizure freedom  0.13  2,119  365.0  0.7536 
Not seizure-free, but retain  0.22  3,040  346.3  0.6126 
Not seizure-free & return to LEV 1,000 mg/day+ST  0.01  3,124  347.2  0.5782 
Not seizure-free & withdraw to ST alone  0.02  2,555  322.1  0.5782 
LEV 3,000 mg/day+ST  0.44  3,873  331.2  0.6528 
Seizure freedom  0.04  3,097  365.0  0.7536 
Not seizure-free, but retain  0.33  4,018  329.0  0.6491 
Not seizure-free & return to LEV 2,000 mg/day+ST  0.00  3,633  322.1  0.6126 
Not seizure-free & withdraw to ST alone  0.07  2,596  322.1  0.5782 
ST alone  1.00 2,380 322.4 0.5801 
Seizure freedom  0.01  0,551 365.0 0.8576 
Not seizure-free  0.99  2,393  322.1  0.5782 
*Cost estimates for each state of combination therapy consisted of the sum of costs for inpatient, outpatient, and pharmacy plus drug 
acquisition cost for each dosage of LEV. Lower costs for each state of combination therapy (than sum of all four costs) were due to 
reduced health resource utilization after use of LEV. LEV: levetiracetam, SFD: seizure-free day, ST: standard therapy, QALY: quality-ad-
justed life year 
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*C: cost, E: effectiveness, Δ: difference 
The net cost is equal to the total cost of combination 
therapy less the total cost of ST. The cost per SFD gained 
is equal to the net costs for LEV treatment per person 
per year, divided by the net SFD gained. The cost per 
QALY gained in this study is equal to the net costs for 
LEV treatment per person per year, divided by the net 
QALYs gained. 
 
Sensitivity analyses 
In order to test the robustness of the model and to eva-
luate the effect of uncertainty around model parameters 
on the ICER, we conducted extensive sensitivity analy-
ses on all the variables in this study. To test the cost pa-
rameter estimates, costs for inpatient, outpatient and ph-
armacy and the acquisition price for LEV were both in-
creased and decreased by 50%, the range that endorsed 
by the SAB. For parameters associated with transitions 
from or to certain doses of LEV, a full range (0-1) of two 
probabilities of better response (originally 0.5) and worse 
response (originally 0.8) were considered.   
 
Results 
 
Characteristics of patients for the trial in Korea
12 
Of a total of 100 Korean patients, 52 (52%) were male 
and 48 (48%) were female. Patients’ mean age (±SD) was 
35.3 (±11.7) years, while the mean age (±SD) at onset of 
epilepsy was 17.8 (±9.5) years. Eighty patients present-
ed with at least one complex partial seizure, 28 patients 
with at least 1 secondarily generalized tonicclonic seizure, 
and 13 patients with at least 1 simple partial seizure dur-
ing the baseline 3-month period.   
In the history of previous AED treatment, 76 patients 
had taken two or more AEDs prior to entry to the study. 
The majority (80%) of patients entered the trial on two 
concomitant AEDs. The most frequently used concomi-
tant AEDs were carbamazepine, valproic acid, lamotrigine, 
and topiramate. 
 
Cost-effectiveness analysis 
 
Effectiveness Estimates 
A patient treated with combination therapy (LEV+ST) 
had 340.7 SFDs per year, while a patient treated with ST 
had 322.4 SFDs per year. The incremental effectiveness 
is therefore 18.3 SFDs per patient per year (Table 2). 
 
Cost Estimates 
Over 1 year of treatment, the inpatient cost for combi-
nation therapy (LEV+ST) is only 64.5% of the inpatient 
cost for ST alone (US$ 1,184 vs. US$ 1,836 respectively). 
The additional cost of LEV for combination therapy is 
US$ 1,443. This shows that the acquisition cost of LEV 
is partially offset by its effectiveness. A patient on com-
bination therapy (LEV+ST) costs US$ 3,178 per year, 
while a patient on ST alone costs US$ 2,380 per year. 
The incremental cost of treating patients with LEV add-
on is therefore US$ 798 per patient per year (Table 3). 
 
Cost-Effectiveness Ratio 
The ICER (=ΔC/ΔE) is US$ 44 per SFD gained per 
patient for LEV add-on (Table 4).  
 
Sensitivity Analyses 
The results of the sensitivity analyses indicated the 
robustness of the model (Table 4). The range of the 
ICER for outpatient costs (±50%; 39-49) and pharmacy 
costs  (±50%; 34-54) were relatively narrow, meaning 
that these two costs had less influence on the cost per 
SFD gained, equivalent to the ICER in the study. The 
cost ranges for inpatients (±50%; 17-70) and the price 
of LEV (±50%; 11-77) were wider. Although we made 
the conservative assumption that 100% of inpatient cost 
is expected when seizure frequency is zero (a state of 
P
better response=0), the ICER was US$ 77 per SFD. Further, 
even when we assumed that patients with worse response 
needed 100% of inpatient costs (a state of P
worse response 
=1), the ICER was US$ 45 per SFD (Table 4). 
 
Cost-utility analysis 
 
Global Evaluation Scale and 31-Item Quality-of-Life 
in Epilepsy Inventory 
The Korean clinical trial reported great improvement 
in global evaluation: improvement in 81% (marked, 41%; 
moderate, 16%: slight, 24%); no change in 16%; and 
worsening (slight) in 3%.
12 No cases with moderate or 
marked worsening of the disease were reported.
12 
 
Quality Adjusted Life Years Gained and Net Cost 
All patients in the combination therapy group gained 
TABLE 3. Cost comparison in patients with combination therapy 
(LEV+ST) versus ST alone of base case scenario 
Treatment arms 
Services 
LEV+ST ST  alone 
Unit 
Inpatient 1,184*  1,836*  US$/Person/Year 
Outpatient 1,834  183  US$/Person/Year 
Pharmacy 3,684 368  US$/Person/Year 
LEV add-on  1,443  0  US$/Person/Year 
*These values are derived from the calculation multiplying unit 
cost for inpatient treatment with the probability that a person 
with refractory e pilepsy will need hospital admission during 1  
year. LEV: levetiracetam, ST: standard therapy   
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0.6522 QALYs per year, while those in the ST alone group 
gained 0.5801 QALYs per year (Table 2). The incremental 
utility was 0.072. As with the cost-effectiveness analysis, 
the incremental cost of treating patients with LEV add-
on is US$ 798 per patient per year. Therefore, cost per 
QALY gained (=ΔC/ΔE) was calculated to be US$ 11,084 
(Table 4). 
 
Sensitivity Analyses 
The results of sensitivity analyses supported the ro-
bustness of the model for cost-utility analysis (Table 4). 
The range of the cost per QALY gained for the outpa-
tient costs (±50%; 9,811-12,358) and the pharmacy costs 
(±50%; 8,528-13,641) were relatively narrow, meaning 
that these two costs had less influence on the cost per 
QALY gained. However, the range for the inpatient cost 
(±50%; 4,423-17,745) and the price of LEV (±50%; 
2,683-19,493) was wider (Table 4). 
When we assumed that 100% of inpatient cost is ex-
pected even when seizure frequency is zero (a state of 
P
better response=0), the cost per QALY gained was US$ 19, 
523. Further, when we assumed that patients with worse 
response needed 100% of inpatient costs (a state of P
worse 
response=1), the cost per QALY gained was US$ 11,544 
(Table 4). 
Discussion 
 
We found that treatment of refractory partial epileptic 
patients with LEV add-on therapy would be expected to 
increase the overall direct medical expenditures, but that 
the additional resources spent on extra drug costs would 
be partially offset by savings resulting from decreases in 
the utilization of other healthcare options (e.g., hospi-
talization). The model assumed the pathways followed 
by patients in actual clinical practice. The health out-
comes considered were based on data derived from a cli-
nical trial in Korea. All assumptions related to the in-
formation that was not available in the trial were clearly 
specified and were approved by the independent panel 
of experts (SAB). Moreover, the model proved to be fl-
exible and can be readily adapted to different practice set-
tings and different cost structure.   
 
Economic evaluation of antiepileptic drug  
addon therapy  
The main health outcome of the analysis, i.e., SFDs, 
was improved by LEV with an incremental gain of 18.3 
days per patient per year, thus resulting in a cost-effec-
tiveness ratio of US$ 44 per SFD gained per patient per 
year. The ICER in this study looks grossly better than 
TABLE 4. Incremental cost and health outcomes associated with the use of LEV. Base case and one-way sensitivity analysis 
Cost effectiveness analysis    Cost utility analysis 
Scenario  1-year cost 
increase, US$ 
SFDs 
gained 
Cost per SFD 
gained, US$ 
 
1-year cost 
increase, US$ 
QALY 
gained 
Cost per QALY 
gained, US$ 
Base case  0,798 18.3  44    ,0798 0.072  11,084 
Price, LEV (US$)            
-50%  0,193 18.3  11    ,0193 0.072  02,683 
+50% 1,404  18.3  77    1,404 0.072  19,493 
Cost for inpatient (US$)            
-50% 1,278  18.3  70    1,278 0.072  17,745 
+50%  0,319 18.3  17    ,0319 0.072  04,423 
Cost for outpatient (US$)*           
-50% 7,064  18.3  39    7,064 0.072  09,811 
+50%  0,890 18.3  49    0,890 0.072  12,358 
Cost for pharmacy (US$)*           
-50%  0,614 18.3  34    0,614 0.072  08,528 
+50%  0,982 18.3  54    0,982 0.072  13,641 
Pbetter response            
0 1,406  18.3  77    1,406 0.072  19,523 
1  0,191 18.3  10    0,191 0.072  02,646 
Pworse response            
0  0,666 18.3  36    0,666 0.072  09,243 
1  0,831 18.3  45    0,831 0.072  11,544 
*These sensitivity analyses were conducted on the assumption that ST arm remained at base case scenario when combination therapy
arm was being changed. LEV: levetiracetam, Pbetter response: probability for better response in the group with better response (i.e., more 
than 50% reduction in seizure frequency)(0.5 at base case), Pworse response: probability for worse response in the group with worse response 
(0.8 at base case), SFD: seizure-free day, ST: standard therapy, QALY: qualityadjusted life year 
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the Canadian report of CAN$ 80.7 per SFD gained.
19 The 
superior ICER obtained here probably reflects different 
direct medical costs between Korea and Canada. Both 
models (Blais et al.
19 and this study) share a common 
methodology using a decision-tree model for LEV add-on 
to ST for refractory epileptic patients and considering 
direct medical costs and SFDs gained as effectiveness. 
LeLorier et al.
23 reported the potential benefit of seizure 
freedom (one additional seizure free patient per year) could 
be gained with a cost of  ￡5,301 by adding LEV to stand-
ard treatment when considering the potential benefit of 
epilepsy surgery in the model. For other AEDs, Markowitz 
et al.
22 found that lamotrigine (LTG) therapy cost an addi-
tional US$ 728 compared with the patients’ current mono-
therapy only, discounted at 3% over 10 years. LTG therapy 
resulted in a gain 106 additional SFDs (undiscounted) and 
an ICER of US$ 6.9 per SFD gained. However, Markowitz 
et al.
22 used the 10-year long-term model, but they did not 
discount outcome (i.e., SFD). Therefore, direct comparison 
of cost per SFD with a 1-year time horizon may not be 
justified. Schachter et al.
24 estimated that adjunctive tia-
gabine (TGB), added to existing treatment of phenytoin, 
cost US$ 719 over 16 weeks including the cost of manag-
ing adverse events, compared with US$ 784 for adjunctive 
carbamazepine (CBZ). CBZ was more clinically effica-
cious (50% reduction in seizure frequency) but more de-
tailed results were not provided. Within the baseline CBZ 
arm, add-on phenytoin (PHT) costs US$ 810 compared 
with US$ 958 for add-on TGB. Add-on PHT and add-on 
TGB had similar efficacy. Compared with current medica-
tion only, Messori et al.
25 found that adjunctive LTG cost 
an additional US$ 1,612,370 for a cohort of 100 patients 
over the patients’ lifetimes, gained 39 QALYs, and cal-
culated an ICER of US$ 41,343 per QALY. When we con-
sider both results of this study, previous economic evalua-
tions of other AEDs, and the Gross Domestic Product of 
Korea (US$ 19,722/year/person, 2006), LEV is compara-
tively cost-effective against older AEDs.   
 
From disease-specific quality of life measurement 
to utilities 
QALYs require a uni-dimensional measurement of QoL 
using both direct (i.e., standard gamble, time trade-off, 
person trade-off, visual analogue scale) and indirect uti-
lity assessments (i.e., EQ-5D, SF-6D, HUI). But, health-
related QoL should be considered multidimensional, so 
it is often measured by disease-specific QoL scales. Th-
erefore, analysis would be facilitated by converting dis-
ease-specific QoL measurement into utilities. Conver-
sion algorithms were derived using 1 of 4 techniques: 1) 
transfer to utility regression, 2) response mapping, 3) ef-
fect size translation, and 4) revaluing outcome measures 
using preference-based scaling techniques.
26 The resul-
tant health state classification system consists of several 
dimensions (i.e., mobility, usual activity, visual acuity, 
pain, cognition, depression) with several levels (i.e., level 
1=no problem, level 2=some problem, level 3=extreme 
problems), thus a generating huge number of health 
states. The valuing processes used in this study may be 
considered relatively new. Contrary to usual methods, 
levels were not categorized in this study, even though 
we used quality weights for 7 dimensions which were 
provided by original authors of QOLIE.
17 Instead, sub-
scale scores ranging from 0 to 100 were used to represent 
multidimensional levels of the health state of a patient. 
In this study, it was assumed that level is a continuous 
(linear), not categorical (stepwise) variable. Whether li-
near or stepwise, a higher score or higher level reflects 
more severe problems. A utility score was computed by 
summing up all utility portions of different dimensions 
in this study, which was adopted from the methodology 
for the EQ-5D Korean version.
27 
 
Limitations 
This study has some limitations. First, as with other 
cost-effectiveness studies, with regard to external validity, 
there is the problem of extrapolating clinical trial data 
(efficacy) to real world clinical practice (effectiveness). 
This problem was addressed through the sensitivity an-
alyses. Second, because of the third-party payer pers-
pective employed in this analysis, indirect costs were not 
considered in the model, even if they were estimated to 
represent a large proportion of the total costs associated 
with epilepsy. In order to gather such information, data 
derived from a long-term observation period must be 
used for this refractory population. Third, the Korean tr-
anslation of the QOLIE-31 has not yet been validated, so 
all results of the cost-utility analysis should be consi-
dered in the light of data from relevant preference-based 
health economic studies. Fourth, we should use quality 
weights from other countries given that there are no prior 
studies that have been carried out in Korea. Special caut-
ion is needed when transferring these data to other contexts. 
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